| Literature DB >> 19373457 |
Erica L T van den Akker1, Jan W Koper, Koen Joosten, Frank H de Jong, Jan A Hazelzet, Steven W J Lamberts, Anita C S Hokken-Koelega.
Abstract
OBJECTIVE: Corticosteroids are used in sepsis treatment to benefit outcome. However, discussion remains on which patients will benefit from treatment. Inter-individual variations in cortisol sensitivity, mediated through the glucocorticoid receptor, might play a role in the observed differences. Our aim was to study changes in mRNA levels of three glucocorticoid receptor splice variants in neutrophils of children with sepsis. PATIENTS ANDEntities:
Mesh:
Substances:
Year: 2009 PMID: 19373457 PMCID: PMC2698978 DOI: 10.1007/s00134-009-1468-6
Source DB: PubMed Journal: Intensive Care Med ISSN: 0342-4642 Impact factor: 17.440
Patient characteristics
| No | Sex | Age (years) | Diagnosis | Ventilated | Admission (days) | GC | PRISM score healthy = 0 | Cortisol (nmol/l) ref < 750 | ACTH (pmol/l) ref < 40 | CRP mg/l ref < 10 | IL-6 pg/ml ref < 10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 1.2 | Meningococcal sepsis | No | 1 | No | 7 | 848 | 365 | ||
| 2 | F | 2.3 | Meningococcal sepsis | No | 1 | No | 13 | 1,349 | 3.5 | 84 | 10,494 |
| 3 | M | 2.7 | Meningococcal sepsis | No | 1 | No | 11 | 638 | 65 | ||
| 4 | F | 2.9 | Meningococcal sepsis | Yes | 1 | Yes | 17 | 1,645 | 156 | 334 | |
| 5 | F | 5.8 | Meningococcal sepsis | Yes | 2 | No | 11 | 1,006 | 4.8 | 229 | 135 |
| 6 | M | 2.4 | Meningococcal sepsis | No | 2 | Yes | 19 | 201 | 2,016 | ||
| 7 | M | 2.1 | Meningococcal sepsis | No | 2 | No | 5 | 619 | 2.0 | 89 | 112 |
| 8 | M | 3.0 | Meningococcal sepsis + shock | Yes | 15 | No | 15 | 696 | 238.0 | 85 | 30,481 |
| 9 | F | 4.0 | Meningococcal sepsis + shock | Yes | 7 | No | 37 | 782 | 141.0 | 25 | 362,333 |
| 10 | M | 0.3 | Meningococcal sepsis + shock | Yes | 13 | No | 14 | 995 | 39.3 | 150 | 13,892 |
| 11 | F | 1.7 | Meningococcal sepsis + shock | Yes | 2 | No | 23 | 601 | 5.2 | 104 | 15,866 |
| 12 | M | 5.1 | Meningococcal sepsis + shock | Yes | 4 | No | 19 | 1,047 | 13.6 | 51 | 49,526 |
| 13 | M | 1.4 | Meningococcal sepsis + shock | Yes | 5 | No | 31 | 244 | 179.0 | 78 | 467,433 |
| 14 | M | 1.8 | Meningococcal sepsis + shock | Yes | 1 | Yes | 14 | 394 | 2.4 | 176 | 688 |
| 15 | M | 2.1 | Meningococcal sepsis + shock | Yes | 2 | Yes | 30 | 2,901 | 1.9 | 408 | 547 |
| 16 | M | 2.8 | Sepsis + shock eci | Yes | 1 | Yes | 20 | 531 | 6.4 | 364 | 6,911 |
| 17 | M | 12.6 | Sepsis eci | No | 0 | No | 3 | 792 | 1.0 | 91 | 44 |
| 18 | M | 7.7 | Sepsis eci | No | 0 | Yes | 1 | 1,162 | 9.5 | 46 | 1,457 |
| 19 | F | 14.6 | Toxic shock syndrome | Yes | 3 | No | 21 | 3,167 | 1.0 | 112 | 50 |
| 20 | F | 3.3 | Toxic shock syndrome | Yes | 13 | No | 20 | 525 | 1.3 | 210 | |
| 21 | F | 0.7 | Pneumococcal sepsis + shock | Yes | 16 | Yes | 29 | 1,241 | 3.2 | 346 | 22,671 |
| 22 | F | 2.4 | Pneumococcal sepsis + shock | Yes | 16 | No | 38 | 2,344 | 141.0 | 53 | |
| 23 | M | 14.8 | Staphylococcal sepsis + shock | Yes | 1 | No | 29 | 1,948 | 4.1 | 323 |
F female, M male, GC glucocorticoid therapy: dexamethasone (no. 4, 6, 14, 16, 18, 21) or hydrocortisone (no. 15), ref healthy reference. One patient died (no. 23), all other children recovered and are alive to date
Fig. 1Levels of glucocorticoid receptor splice variants GR-α, GR-P, and GR-β mRNA in neutrophils of children with sepsis, measured at day 0, 3, 7 and after recovery (X-axis). Y-axis represents mRNA levels (copies) measured by real-time polymerase chain reaction. The dotted reference lines represent the ±2 SD of healthy adults
Fig. 2Longitudinal samples obtained from the seven sepsis patients with complete dataset for day 0, 3 and after recovery (X-axis). The Y-axis represents individual levels of glucocorticoid receptor splice variants GR-α, GR-P, and GR-β mRNA in neutrophils of these patients
Correlation of glucocorticoid receptor mRNA levels with patient characteristics
| CC | CC | CC | ||||
|---|---|---|---|---|---|---|
| GR-α | GR-P | GR-β | ||||
| Age | 0.53 | 0.01 | 0.35 | 0.10 | −0.16 | 0.95 |
| PRISM | −0.16 | 0.47 | −0.14 | 0.52 | −0.17 | 0.94 |
| CRP | 0.25 | 0.91 | −0.79 | 0.72 | −0.54 | 0.82 |
| IL-6 | −0.60 | 0.009 | −0.49 | 0.04 | −0.17 | 0.51 |
| Cortisol | 0.30 | 0.18 | 0.15 | 0.52 | 0.15 | 0.52 |
| ACTH | 0.38 | 0.11 | −0.32 | 0.18 | 0.17 | 0.49 |
CC Correlation coefficient, GR glucocorticoid receptor, PRISM pediatric risk of mortality score, CRP C-reactive protein
Fig. 3Correlation between Interleukin-6 and GR-α mRNA levels at t = 0 and correlation between age and GR-α mRNA levels at t = 0
Mean glucocorticoid receptor mRNA expression at t = 0 grouped by sex, diagnosis or medication
| GR-α | GR-P | GR-β | |||||
|---|---|---|---|---|---|---|---|
| Gender | |||||||
| Male | 13 | 1.27 | 0.92 | 0.18 | 0.89 | 0.0012 | 0.21 |
| Female | 10 | 1.23 | 0.19 | 0.0048 | |||
| Shock | |||||||
| Yes | 14 | 1.19 | 0.67 | 0.18 | 0.94 | 0.0014 | 0.19 |
| No | 9 | 1.36 | 0.19 | 0.0055 | |||
| Diagnosis: meningococcal | |||||||
| Yes | 15 | 1.11 | 0.29 | 0.15 | 0.23 | 0.0036 | 0.44 |
| No | 8 | 1.54 | 0.24 | 0.0013 | |||
| Length of ICU stay <7 days | |||||||
| Yes | 16 | 1.34 | 0.52 | 0.18 | 0.83 | 0.0032 | 0.66 |
| Nob | 7 | 1.07 | 0.20 | 0.0018 | |||
| Glucocorticoids | |||||||
| No | 16 | 1.45 | 0.14 | 0.23 | 0.04 | 0.0015 | 0.23 |
| Yes | 7 | 0.82 | 0.08 | 0.0052 | |||
| Ethomidate | |||||||
| No | 18 | 1.43 | 0.09 | 0.21 | 0.27 | 0.0031 | 0.70 |
| Yes | 5 | 0.65 | 0.11 | 0.0017 | |||
| Midazolam | |||||||
| No | 10 | 1.38 | 0.59 | 0.20 | 0.72 | 0.0013 | 0.44 |
| Yes | 13 | 1.17 | 0.17 | 0.0036 | |||
| Inotropic support | |||||||
| No | 8 | 1.48 | 0.71 | 0.2 | 0.73 | 0.0011 | 0.64 |
| Yes | 15 | 1.14 | 0.18 | 0.0036 | |||
aComparion of means by one-way ANOVA
bDeceased patient was analysed in the group of ICU stay >7 days